Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

DUBLIN--(BUSINESS WIRE)--The "Liraglutide and Semaglutide Market by Type, by Route of Administration, by Application, by Distribution Channel, and by Region" report has been added to ...

Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year ...

KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that ...

This study provides valuable guidance for doctors and patients when choosing diabetes medications. It confirms that ...

Hims plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide and tirzepatide. Despite the setback, Hims shows strong financial health with 77% Y ...

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK.

Czech Republic-based Zentiva Pharma, a generics and over-the-counter medicines company that is wholly-owned by private equity ...

Victoza (liraglutide) is a prescription drug used to help manage type 2 diabetes and reduce the risk of certain diabetes-related heart problems. Victoza is given as a daily injection under the skin.

Adding the glucagon-like peptide 1 receptor agonist (GLP-1 RA) liraglutide to standard therapy reduces the risk for recurrent stroke in patients with type 2 diabetes (T2D) and a minor acute ...

Detailed price information for Lexaria Bioscience Corp WT (LEXXW-Q) from The Globe and Mail including charting and trades.